Pharma Mar Gestione
Criteri Gestione verificati 2/4
Pharma Mar Il CEO è Jose Fernandez Sousa-Faro, nominato in Jan1986, ha un mandato di 40.33 anni. possiede direttamente 6.43% delle azioni della società, per un valore di € 111.99M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 15.2 anni e 3.9 anni.
Informazioni chiave
Jose Fernandez Sousa-Faro
Amministratore delegato
n/a
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | 40.3yrs |
| Proprietà del CEO | 6.4% |
| Durata media del management | 15.2yrs |
| Durata media del Consiglio di amministrazione | 3.9yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Pharma Mar's (BME:PHM) Solid Profits Have Weak Fundamentals
Despite posting some strong earnings, the market for Pharma Mar, S.A.'s ( BME:PHM ) stock hasn't moved much. We did...There May Be Underlying Issues With The Quality Of Pharma Mar's (BME:PHM) Earnings
Pharma Mar, S.A.'s ( BME:PHM ) robust earnings report didn't manage to move the market for its stock. We did some...Pharma Mar, S.A. (BME:PHM) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Pharma Mar, S.A. ( BME:PHM ) last week reported its latest third-quarter results, which makes it a good time for...Is Pharma Mar (BME:PHM) A Risky Investment?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Risks To Shareholder Returns Are Elevated At These Prices For Pharma Mar, S.A. (BME:PHM)
It's not a stretch to say that Pharma Mar, S.A.'s ( BME:PHM ) price-to-sales (or "P/S") ratio of 7.4x right now seems...Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.80
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.80 on 27th...Pharma Mar (BME:PHM) Has Announced That It Will Be Increasing Its Dividend To €0.80
Pharma Mar, S.A. ( BME:PHM ) will increase its dividend from last year's comparable payment on the 27th of June to...
ZEPZELCA's EMA Submission Will Broaden Cancer Treatment Availability In Europe
Successful approval of ZEPZELCA in Europe and new markets could significantly boost PharmaMar’s future revenues, leveraging positive trial results.We Think Shareholders Should Be Aware Of Some Factors Beyond Pharma Mar's (BME:PHM) Profit
The latest earnings release from Pharma Mar, S.A. ( BME:PHM ) disappointed investors. Our analysis found several...There's Reason For Concern Over Pharma Mar, S.A.'s (BME:PHM) Massive 27% Price Jump
The Pharma Mar, S.A. ( BME:PHM ) share price has done very well over the last month, posting an excellent gain of 27...Pharma Mar, S.A.'s (BME:PHM) Price Is Right But Growth Is Lacking After Shares Rocket 55%
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 55% gain in the last month alone. The...Pharma Mar, S.A.'s (BME:PHM) Share Price Boosted 27% But Its Business Prospects Need A Lift Too
Pharma Mar, S.A. ( BME:PHM ) shares have continued their recent momentum with a 27% gain in the last month alone...Pharma Mar (BME:PHM) Will Pay A Larger Dividend Than Last Year At €0.65
Pharma Mar, S.A.'s ( BME:PHM ) dividend will be increasing from last year's payment of the same period to €0.65 on 14th...Pharma Mar, S.A.'s (BME:PHM) Shares Bounce 29% But Its Business Still Trails The Industry
Pharma Mar, S.A. ( BME:PHM ) shareholders would be excited to see that the share price has had a great month, posting a...Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Last week, you might have seen that Pharma Mar, S.A. ( BME:PHM ) released its annual result to the market. The early...Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pharma Mar fair value estimate is €52.37 Pharma Mar is...We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Pharma Mar, S.A.'s ( BME:PHM ) lackluster earnings announcement last week disappointed investors. We think that they...Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Market forces rained on the parade of Pharma Mar, S.A. ( BME:PHM ) shareholders today, when the analysts downgraded...Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued
Today we will run through one way of estimating the intrinsic value of Pharma Mar, S.A. ( BME:PHM ) by estimating the...AMMINISTRATORE DELEGATO
Jose Fernandez Sousa-Faro
Mr. José María Fernández Sousa-Faro, Ph D., founded Pharma Mar, S.A.U. in 1986. He Founded Noscira, S.A., in 2000.He serves as the Chief Executive Officer and President of Pharma Mar, S.A.U. He serves as...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | 40.3yrs | €294.00k | 6.43% € 111.1m | |
| Executive Vice-Chairman | no data | €124.00k | 0.00058% € 10.0k | |
| Founder | no data | Nessun dato | Nessun dato | |
| Chief Financial Officer | 26.3yrs | Nessun dato | Nessun dato | |
| Head of Capital Markets & Investor Relations | 11.3yrs | Nessun dato | Nessun dato | |
| General Counsel & Secretary of the Board of Directors | 6.7yrs | Nessun dato | Nessun dato | |
| Global Compliance Head | 6yrs | Nessun dato | Nessun dato | |
| Communication Director | no data | Nessun dato | Nessun dato | |
| Director of Corporate Development | 4.3yrs | Nessun dato | Nessun dato | |
| Director of Human Resources & IT | 22.8yrs | Nessun dato | Nessun dato | |
| Managing Director of Oncology & Virology Business Units | 19.1yrs | Nessun dato | Nessun dato | |
| Senior Vice President of Strategic Development | no data | Nessun dato | Nessun dato |
Gestione esperta: Il team dirigenziale di PHM è esperto e expertise (durata media dell'incarico 15.2 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Founder | no data | €294.00k | 6.43% € 111.1m | |
| Executive Vice-Chairman | no data | €124.00k | 0.00058% € 10.0k | |
| Independent Other External Director | 5.3yrs | €35.00k | 0.062% € 1.1m | |
| Independent Other External Director | no data | €35.00k | Nessun dato | |
| Proprietary Director | no data | €34.00k | 5.51% € 95.2m | |
| Independent Director | 7.3yrs | Nessun dato | 0.010% € 179.1k | |
| Representative Proprietary Director | 5.4yrs | Nessun dato | Nessun dato | |
| Independent Director | 3.9yrs | Nessun dato | 0.010% € 179.1k | |
| Independent Coordinating Director | 3.9yrs | Nessun dato | Nessun dato | |
| Independent Director | 3.9yrs | Nessun dato | Nessun dato | |
| Independent Other External Director | no data | Nessun dato | 0.010% € 179.1k | |
| Independent Director | 3yrs | Nessun dato | Nessun dato |
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di PHM sono considerati esperti (durata media dell'incarico 3.9 anni).
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/05/11 22:04 |
| Prezzo dell'azione a fine giornata | 2026/05/11 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Pharma Mar, S.A. è coperta da 12 analisti. 8 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Jaime Escribano | Banco Santander |
| Patricia Cifuentes | Bestinver Sociedad De Valores, S.A |
| Kambiz Yazdi | BTIG |